226 related articles for article (PubMed ID: 29097257)
1. A randomized, 13-week study assessing the efficacy and metabolic effects of paliperidone palmitate injection and olanzapine in first-episode schizophrenia patients.
Huang M; Yu L; Pan F; Lu S; Hu S; Hu J; Chen J; Jin P; Qi H; Xu Y
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():122-130. PubMed ID: 29097257
[TBL] [Abstract][Full Text] [Related]
2. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.
Schreiner A; Niehaus D; Shuriquie NA; Aadamsoo K; Korcsog P; Salinas R; Theodoropoulou P; Fernández LG; Uçok A; Tessier C; Bergmans P; Hoeben D
J Clin Psychopharmacol; 2012 Aug; 32(4):449-57. PubMed ID: 22722501
[TBL] [Abstract][Full Text] [Related]
3. A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients.
Hu S; Yao M; Peterson BS; Xu D; Hu J; Tang J; Fan B; Liao Z; Yuan T; Li Y; Yue W; Wei N; Zhou W; Huang M; Xu Y
Psychopharmacology (Berl); 2013 Nov; 230(1):3-13. PubMed ID: 23559220
[TBL] [Abstract][Full Text] [Related]
4. A Flexible-Dose Study of Paliperidone ER in Patients With Nonacute Schizophrenia Previously Treated Unsuccessfully With Oral Olanzapine.
Kotler M; Dilbaz N; Rosa F; Paterakis P; Milanova V; Smulevich AB; Lahaye M; Schreiner A
J Psychiatr Pract; 2016 Jan; 22(1):9-21. PubMed ID: 26813484
[TBL] [Abstract][Full Text] [Related]
5. Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics.
Hargarter L; Cherubin P; Bergmans P; Keim S; Rancans E; Bez Y; Parellada E; Carpiniello B; Vidailhet P; Schreiner A
Prog Neuropsychopharmacol Biol Psychiatry; 2015 Apr; 58():1-7. PubMed ID: 25448776
[TBL] [Abstract][Full Text] [Related]
6. Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.
Kim E; Correll CU; Mao L; Starr HL; Alphs L
CNS Spectr; 2016 Dec; 21(6):466-477. PubMed ID: 27629292
[TBL] [Abstract][Full Text] [Related]
7. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia.
Schreiner A; Aadamsoo K; Altamura AC; Franco M; Gorwood P; Neznanov NG; Schronen J; Ucok A; Zink M; Janik A; Cherubin P; Lahaye M; Hargarter L
Schizophr Res; 2015 Dec; 169(1-3):393-399. PubMed ID: 26431793
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.
Davidson M; Emsley R; Kramer M; Ford L; Pan G; Lim P; Eerdekens M
Schizophr Res; 2007 Jul; 93(1-3):117-30. PubMed ID: 17466492
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
Li H; Rui Q; Ning X; Xu H; Gu N
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
[TBL] [Abstract][Full Text] [Related]
10. Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics.
Kwon JS; Kim SN; Han J; Lee SI; Chang JS; Choi JS; Lee HJ; Cho SJ; Jun TY; Lee SH; Han C; Lee KU; Lee KK; Lee E
Int Clin Psychopharmacol; 2015 Nov; 30(6):320-8. PubMed ID: 26196188
[TBL] [Abstract][Full Text] [Related]
11. A Randomized, 8-Week Study of the Effects of Extended-Release Paliperidone and Olanzapine on Heart Rate Variability in Patients With Schizophrenia.
Pu ZP; Li GR; Zou ZP; Tao F; Hu SH
J Clin Psychopharmacol; 2019; 39(3):243-248. PubMed ID: 30925499
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study.
Savitz AJ; Lane R; Nuamah I; Gopal S; Hough D
J Am Acad Child Adolesc Psychiatry; 2015 Feb; 54(2):126-137.e1. PubMed ID: 25617253
[TBL] [Abstract][Full Text] [Related]
13. A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents.
Schreiner A; Bergmans P; Cherubin P; Keim S; Rancans E; Bez Y; Parellada E; Carpiniello B; Vidailhet P; Hargarter L
Clin Ther; 2014 Oct; 36(10):1372-88.e1. PubMed ID: 25444566
[TBL] [Abstract][Full Text] [Related]
14. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
[TBL] [Abstract][Full Text] [Related]
15. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
Hough D; Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M
Schizophr Res; 2010 Feb; 116(2-3):107-17. PubMed ID: 19959339
[TBL] [Abstract][Full Text] [Related]
16. Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate.
Sliwa JK; Fu DJ; Bossie CA; Turkoz I; Alphs L
BMC Psychiatry; 2014 Feb; 14():52. PubMed ID: 24559194
[TBL] [Abstract][Full Text] [Related]
17. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia.
Naber D; Hansen K; Forray C; Baker RA; Sapin C; Beillat M; Peters-Strickland T; Nylander AG; Hertel P; Andersen HS; Eramo A; Loze JY; Potkin SG
Schizophr Res; 2015 Oct; 168(1-2):498-504. PubMed ID: 26232241
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Safety of Paliperidone Extended Release in Adolescents with Schizophrenia: An Open-Label, Flexible Dose Study.
Savitz A; Lane R; Nuamah I; Singh J; Hough D; Gopal S
J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):548-57. PubMed ID: 26218669
[TBL] [Abstract][Full Text] [Related]
19. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.
Narula PK; Rehan HS; Unni KE; Gupta N
Schizophr Res; 2010 May; 118(1-3):218-23. PubMed ID: 20207521
[TBL] [Abstract][Full Text] [Related]
20. A pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophrenia.
Alphs L; Mao L; Lynn Starr H; Benson C
Schizophr Res; 2016 Feb; 170(2-3):259-64. PubMed ID: 26742509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
